ASCO releases clinical practice guideline for pancreatic cancer
A clinical practice guideline offers recommendations on the best course of treatment for patients with potentially treatable pancreatic cancer.
A clinical practice guideline offers recommendations on the best course of treatment for patients with potentially treatable pancreatic cancer.
Median overall survival was 11.9 months in patients receiving gemcitabine plus erlotinib.
Nearly 85% of patients achieved significant pain relief at 1-year follow up.
Children with recurrent acute or chronic pancreatitis are likely to have high healthcare costs and a high risk for repeat hospitalization.
How can a clinician distinguish chronic pancreatitis from acute pancreatitis in a patient with alcohol-abuse history?
Higher prediagnostic BMI also linked to more advanced disease at diagnosis.
The FDA has approved Ultresa and Viokace to aid food digestion in patients with pancreatic enzyme deficiencies.